Compliance Rate
Compliance Rate
40.0%
Compliant submissions
2
Incompliant submissions
3
Total trials
5
My Organizations' Clinical Trials
Showing 1800 of 2418 entries
View as:
Phase: N/A
Priority: Normal
Start: 02/22/24
End: 10/31/28
Due: 10/31/29
Phase: N/A
Priority: Normal
Start: 06/30/11
End: 01/31/22
Due: 01/31/23
Phase: N/A
Priority: Normal
Start: 02/28/15
End: 07/31/21
Due: 07/31/22
Phase: N/A
Priority: Normal
Start: 12/31/15
End: 12/31/18
Due: 12/31/19
Neoadjuvant Chemotherapy Using Doxorubicin and Paclitaxel in Treating Women With Large Breast Cancer
Phase: N/A
Priority: Normal
Start: 02/29/00
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 12/31/02
End: 09/30/03
Due: 09/30/04
Phase: N/A
Priority: Normal
Start: 03/15/19
End: 11/03/21
Due: 11/03/22
Phase: N/A
Priority: Normal
Start: 05/31/10
End: 04/30/11
Due: 04/30/12
Phase: N/A
Priority: Normal
Start: 01/31/16
End: 04/30/22
Due: 04/30/23
Phase: N/A
Priority: Normal
Start: 07/31/12
End: 04/30/14
Due: 04/30/15
Phase: N/A
Priority: Normal
Start: 02/10/20
End: 12/31/22
Due: 12/31/23
Phase: N/A
Priority: Normal
Start: 10/31/03
End: 02/28/11
Due: 02/28/12
Phase: N/A
Priority: Normal
Start: 01/31/09
End: 02/28/11
Due: 02/28/12
Phase: N/A
Priority: Normal
Start: 07/31/03
End: 06/30/11
Due: 06/30/12
Phase: N/A
Priority: Normal
Start: 12/09/19
End: 03/01/20
Due: 03/01/21
Phase: N/A
Priority: Normal
Start: 01/31/09
End: 03/31/15
Due: 03/31/16
Phase: N/A
Priority: Normal
Start: 11/30/03
End: 01/31/11
Due: 01/31/12
Phase: N/A
Priority: Normal
Start: 01/31/09
End: 04/30/11
Due: 04/30/12
Phase: N/A
Priority: Normal
Start: 07/31/12
End: 08/31/13
Due: 08/31/14
Phase: N/A
Priority: Normal
Start: 01/31/11
End: 04/30/12
Due: 04/30/13
Phase: N/A
Priority: Normal
Start: 08/01/23
End: 02/01/25
Due: 02/01/26
Phase: N/A
Priority: Normal
Start: 04/01/19
End: 01/31/24
Due: 01/31/25
Phase: N/A
Priority: Normal
Start: 08/17/16
End: 12/31/24
Due: 12/31/25
Phase: N/A
Priority: Normal
Start: 09/30/13
End: 10/31/16
Due: 10/31/17
Phase: N/A
Priority: Normal
Start: 07/01/22
End: 12/01/22
Due: 12/01/23